Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Clinical Cancer Research

• Publication date

  2001-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 11309344
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.

  2001cited by this paper
• Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.

  2000cited by this paper
• Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein.

  2000influential reference
• Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6

  2000influential reference
• Erratum: A multidrug resistance transporter from human MCF-7 breast cancer cells (Proceedings of the National Academy of Sciences of the USA (December 22, 1998) 95 (15665-15670))

  1999cited by this paper
• Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes.

  1999cited by this paper
• Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines.

  1999cited by this paper
• Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter.

  1999cited by this paper
• Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells.

  1999cited by this paper
• Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.

  1999cited by this paper
• Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR.

  1999cited by this paper
• Advances in Brief Overexpression of the BCRP / MXR / ABCP Gene in a Topotecan-selected Ovarian Tumor Cell Line 1

  1999influential reference
• The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin.

  1999cited by this paper
• Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice

  1998cited by this paper
• A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance.

  1998cited by this paper
• Antitumour activity of DX-8951f: a new camptothecin derivative.

  1998cited by this paper
• Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A.

  1998cited by this paper
• Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C.

  1998influential reference
• Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro

  1998cited by this paper
• A multidrug resistance transporter from human MCF-7 breast cancer cells.

  1998cited by this paper
• Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.

  1998cited by this paper
• Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.

  1998cited by this paper
• Co-administration of cyclosporin enables oral therapy with paclitaxel.

  1998cited by this paper
• Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.

  1997cited by this paper
• Effect of the multidrug inhibitor GG918 on drug sensitivity of human leukemic cells

  1997cited by this paper
• Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.

  1997cited by this paper
• DX‐8951F, a water‐soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN‐38‐resistant variant

  1997influential reference
• Characterization of phosphine complexes of technetium(III) as transport substrates of the multidrug resistance P-glycoprotein and functional markers of P-glycoprotein at the blood-brain barrier.

  1997cited by this paper
• Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.

  1997cited by this paper
• Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine.

  1997influential reference
• Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients.

  1996cited by this paper
• Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor.

  1996cited by this paper
• Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin.

  1995cited by this paper
• High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma.

  1995cited by this paper
• High-performance liquid chromatographic procedures for the quantitative determination of paclitaxel (Taxol) in human urine.

  1995cited by this paper
• Sequential modifications of topoisomerase I activity in a camptothecin-resistant cell line established by progressive adaptation.

  1993cited by this paper
• High-performance liquid chromatographic procedure for the quantitative determination of paclitaxel (Taxol) in human plasma.

  1993cited by this paper
• In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative.

  1993cited by this paper
• Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue.

  1992cited by this paper
• The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines.

  1991cited by this paper
• Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content.

  1990cited by this paper
• Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody.

  1990cited by this paper
• Pharmacology of drugs that alter multidrug resistance in cancer.

  1990cited by this paper
• Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice.

  1985cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper

• Expression and interaction of RNA binding protein HuR with multidrug transporters (P-GP, MRP1, and ABCG2) in chemoresistant breast and colorectal cancer cells

  2025cites this paper
• Elacridar Inhibits BCRP Protein Activity in 2D and 3D Cell Culture Models of Ovarian Cancer and Re-Sensitizes Cells to Cytotoxic Drugs

  2025cites this paper
• Recent Strategies to Overcome Breast Cancer Resistance.

  2024cites this paper
• ABCG2 Expression as a Potential Survival Predictor in Human Gliomas

  2024cites this paper
• Recent advances in BCRP‐induced breast cancer resistance treatment with marine‐based natural products

  2023cites this paper
• Acetic acid enhances the effect of photodynamic therapy in gastric cancer cells via the production of reactive oxygen species

  2022cites this paper
• The Tetrahydroisoquinoline Scaffold in ABC Transporter Inhibitors that Act as Multidrug Resistance (MDR) Reversers.

  2022cites this paper
• Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients

  2022cites this paper
• Co-administration of MDR1 and BCRP or EGFR/PI3K inhibitors overcomes lenvatinib resistance in hepatocellular carcinoma

  2022cites this paper
• Mechanistic Computational Models of Epithelial Cell Transporters-the Adorned Heroes of Pharmacokinetics

  2021cites this paper
• A Phenylfurocoumarin Derivative Reverses ABCG2-Mediated Multidrug Resistance In Vitro and In Vivo

  2021cites this paper
• Disruption of small molecule transporter systems by Transporter‐Interfering Chemicals (TICs)

  2020cites this paper
• P-glycoprotein Expression Is Upregulated in a Pre-Clinical Model of Traumatic Brain Injury

  2020cites this paper
• Physiological Roles of ERM Proteins and Transcriptional Regulators in Supporting Membrane Expression of Efflux Transporters as Factors of Drug Resistance in Cancer

  2020cites this paper
• Breast Cancer Resistance Protein: A Potential Therapeutic Target for Cancer.

  2020cites this paper
• Efflux transporters in cancer resistance: Molecular and functional characterization of breast cancer resistance protein

  2020cites this paper
• Regulation of breast cancer resistance protein and P‐glycoprotein by ezrin, radixin and moesin in lung, intestinal and renal cancer cell lines

  2020cites this paper
• University of Southern Denmark Abcg2 protein levels and association to response to first-line irinotecan-based therapy for patients with metastatic colorectal cancer Palshof,

  2020cites this paper
• ABCG2 Protein Levels and Association to Response to First-Line Irinotecan-Based Therapy for Patients with Metastatic Colorectal Cancer

  2020cites this paper
• Nonionic surfactants modulate the transport activity of ATP-binding cassette (ABC) transporters and solute carriers (SLC): Relevance to oral drug absorption.

  2019cites this paper
• Identification of anticancer OATP2B1 substrates by an in vitro triple-fluorescence-based cytotoxicity screen

  2019cites this paper
• ABC Transporter-Mediated Multidrug-Resistant Cancer.

  2019cites this paper
• Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells

  2019influential citation
• Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR.

  2018cites this paper
• RETRACTED ARTICLE: Preparation and characterization of surface-modified PLGA-polymeric nanoparticles used to target treatment of intestinal cancer

  2018cites this paper
• In vitro evaluation of the efficacy of selected medicinal plant extracts against multidrug resistant cancer cells

  2017cites this paper
• PharmGKB summary: very important pharmacogene information for ABCG2

  2017cites this paper
• Pharmacokinetic interactions in mice between irinotecan and MBL‐II‐141, an ABCG2 inhibitor

  2017cites this paper
• ABCG2/BCRP: Specific and Nonspecific Modulators

  2017cites this paper
• 9-Deazapurines as Broad-Spectrum Inhibitors of the ABC Transport Proteins P-Glycoprotein, Multidrug Resistance-Associated Protein 1, and Breast Cancer Resistance Protein.

  2017cites this paper
• Population Pharmacokinetics of Oral Topotecan in Infants and Very Young Children with Brain Tumors Demonstrates a Role of ABCG2 rs4148157 on the Absorption Rate Constant

  2016cites this paper
• Emerging role of NRF2 in chemoresistance by regulating drug-metabolizing enzymes and efflux transporters

  2016cites this paper
• Thiosemicarbazones Target Multiple Resistance Pathways in Cancer

  2016cites this paper
• Cancer chemoresistance; biochemical and molecular aspects: a brief overview.

  2016cites this paper
• A potentially functional polymorphism in ABCG2 predicts clinical outcome of non-small cell lung cancer in a Chinese population

  2016cites this paper
• Roles of ATP binding cassette transporters in drug sensitivity and physiology of Plasmodium parasites

  2016cites this paper
• Novel ABCG2 Antagonists Reverse Topotecan-Mediated Chemotherapeutic Resistance in Ovarian Carcinoma Xenografts

  2016cites this paper
• New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies

  2015cites this paper
• Pharmacogenomics of Methotrexate Membrane Transport Pathway: Can Clinical Response to Methotrexate in Rheumatoid Arthritis Be Predicted?

  2015cites this paper
• Mechanisms of regulation of P-glycoprotein and breast cancer resistance protein at the blood-brain barrier : focus on the role of morphine, and P-glycoprotein activation

  2015cites this paper
• Resveratrol-mediated reversal of tumor multi-drug resistance.

  2015cites this paper
• BCRP/ABCG2 inhibitors: a patent review (2009 – present)

  2015cites this paper
• PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.

  2015cites this paper
• Stabilization of the Karenitecin® lactone by alpha-1 acid glycoprotein

  2015cites this paper
• Quantitative interactome analysis reveals a chemoresistant edgotype

  2015cites this paper
• PET Imaging of ABC Transporters in the BBB

  2014cites this paper
• Tariquidar inhibits P-glycoprotein drug efflux but activates ATPase activity by blocking transition to an open conformation.

  2014cites this paper
• The role of ABC transporters in the regulation of uterine contractility in rat

  2014cites this paper
• Influence of active efflux transport on the distribution of targeted agents to brain tumors

  2014cites this paper
• Determinants of the activity and substrate recognition of breast cancer resistance protein (ABCG2)

  2014cites this paper
• Atovaquone and quinine anti-malarials inhibit ATP binding cassette transporter activity

  2014cites this paper
• [Single nucleotide polymorphisms in lung cancer patients and cisplatin treatment].

  2014cites this paper
• Structure and function of BCRP, a broad specificity transporter of xenobiotics and endobiotics

  2014cites this paper
• Human ABC transporters at blood-CNS interfaces as determinants of CNS drug penetration.

  2014cites this paper
• Modulating Drug Resistance by Targeting BCRP/ABCG2 Using Retrovirus-Mediated RNA Interference

  2014cites this paper
• An Electrically Tight In Vitro Blood–Brain Barrier Model Displays Net Brain-to-Blood Efflux of Substrates for the ABC Transporters, P-gp, Bcrp and Mrp-1

  2014cites this paper
• Breast cancer resistance protein (BCRP) and excision repair cross complement-1 (ERCC1) expression in esophageal cancers and response to cisplatin and irinotecan based chemotherapy.

  2014cites this paper
• Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance

  2014cites this paper
• The role of ABC transporters in anticancer drug transport

  2014influential citation
• Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transport—an Update

  2014cites this paper
• In vitro cell models in predicting blood-brain barrier permeability of drugs

  2013cites this paper
• Möglichkeiten der Überwindung von Chemoresistenz beim kindlichen Rhabdomyosarkom

  2013cites this paper
• Reversal of multidrug resistance by the inhibition of ATP-binding cassette pumps employing "Generally Recognized As Safe" (GRAS) nanopharmaceuticals: A review.

  2013cites this paper
• Title page Tariquidar and elacridar are dose-dependently transported by P-glycoprotein and Bcrp at the blood-brain barrier: a small-animal PET and in-vitro study

  2013cites this paper
• Predicting substrates of the human breast cancer resistance protein using a support vector machine method

  2013cites this paper
• Clinical pharmacology of novel anticancer drug formulations

  2013cites this paper
• multiple myeloma ABCG2 expression, function, and promoter methylation in human

  2013cites this paper
• Development of New Breast Cancer Resistance Protein Inhibitors

  2013cites this paper
• Interactions of the Multidrug Resistance Modulators Tariquidar and Elacridar and their Analogues with P‐glycoprotein

  2013cites this paper
• ADME in Drug Discovery

  2013cites this paper
• Increase of the uterus-relaxant effect of nifedipine by the Abcg2 efflux protein inhibitor KO134 in the rat in vivo.

  2013cites this paper
• Tariquidar and elacridar are dose-dependently transported by P-glycoprotein and Bcrp at the blood-brain barrier: a small-animal PET and in-vitro study

  2013cites this paper
• Pharmacokinetic Assessment of Efflux Transport in Sunitinib Distribution to the Brain

  2013influential citation
• Molecular Pharmacology of ABCG2 and Its Role in Chemoresistance

  2013influential citation
• Tariquidar and Elacridar Are Dose-Dependently Transported by P-Glycoprotein and Bcrp at the Blood-Brain Barrier: A Small-Animal Positron Emission Tomography and In Vitro Study

  2013cites this paper
• Effect of genistein, a natural soy isoflavone, on the pharmacokinetics and intestinal toxicity of irinotecan hydrochloride in rats

  2013cites this paper
• An isoquinoline alkaloid from the Chinese herbal plant Corydalis yanhusuo W.T. Wang inhibits P-glycoprotein and multidrug resistance-associate protein 1.

  2013cites this paper
• The Roles of Membrane Transporters on the Oral Drug Absorption

  2013cites this paper
• Oral Anticancer Drugs: Mechanisms of Low Bioavailability and Strategies for Improvement

  2013cites this paper
• Camptothecin resistance in cancer: insights into the molecular mechanisms of a DNA-damaging drug.

  2013cites this paper
• Topoisomerase I Inhibitors: Chemical Biology

  2012cites this paper
• Neuroblastome, résistance in vivo à l'irinotecan et voie de signalisation ALK

  2012influential citation
• Secondary Metabolites from Plants Inhibiting ABC Transporters and Reversing Resistance of Cancer Cells and Microbes to Cytotoxic and Antimicrobial Agents

  2012cites this paper
• Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.

  2012cites this paper
• Pharmacokinetic Modeling to Assess Factors Affecting the Oral Bioavailability of the Lactone and Carboxylate Forms of the Lipophilic Camptothecin Analogue AR-67 in Rats

  2012cites this paper
• CNS Penetration of Tyrosine Kinase Inhibitors in Mouse Models

  2012influential citation
• Human ABCG2: structure, function, and its role in multidrug resistance.

  2012influential citation
• Overcoming Multidrug Resistance via Photodestruction of ABCG2-Rich Extracellular Vesicles Sequestering Photosensitive Chemotherapeutics

  2012cites this paper
• The contribution of the ABCG2 C421A polymorphism to cancer susceptibility: a meta-analysis of the current literature

  2012cites this paper
• Tyrosine Kinase Inhibitors Influence ABCG2 Expression in EGFR‐Positive MDCK BCRP Cells via the PI3K/Akt Signaling Pathway

  2012cites this paper
• RETRACTED ARTICLE: Dual approach utilizing self microemulsifying technique and novel P-gp inhibitor for effective delivery of taxanes

  2012cites this paper
• Intestinal transporters for endogenic and pharmaceutical organic anions: the challenges of deriving in‐vitro kinetic parameters for the prediction of clinically relevant drug–drug interactions

  2012cites this paper
• In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2).

  2011cites this paper
• A prediction model of substrates and non-substrates of breast cancer resistance protein (BCRP) developed by GA-CG-SVM method

  2011cites this paper
• Structure and Function of ABCG2-Rich Extracellular Vesicles Mediating Multidrug Resistance

  2011cites this paper
• The ABCG family of membrane‐associated transporters: you don't have to be big to be mighty

  2011influential citation
• Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP).

  2011cites this paper
• Piperine, a piperidine alkaloid from Piper nigrum re-sensitizes P-gp, MRP1 and BCRP dependent multidrug resistant cancer cells.

  2011cites this paper
• In vitro and in vivo efficacy of edelfosine-loaded lipid nanoparticles against glioma.

  2011cites this paper
• Induction of apoptosis in colon cancer cells by a novel topoisomerase I inhibitor TopIn.

  2011cites this paper